{
    "info": {
        "nct_id": "NCT04947319",
        "official_title": "An Open-label Phase II Study to Investigate the Efficacy, Safety, and Pharmacokinetics of Tirabrutinib in Patients With Primary Central Nervous System Lymphoma (PCNSL)",
        "inclusion_criteria": "Inclusion Criteria (Part A)\n\n1. Written informed consent by the patient prior to screening\n2. Patients aged ≥ 18 years on the day of consenting to the study\n3. Pathologic diagnosis of PCNSL\n4. Relapse or refractory PCNSL with at least one prior high dose methotrexate (HD-MTX) based therapy for PCNSL\n5. Measurable brain lesion with a minimum diameter > 1.0 cm in gadolinium enhanced magnetic resonance imaging (MRI) performed within 14 days before starting tirabrutinib treatment\n6. Eastern Cooperative Oncology Group performance score (ECOG PS) of 0, 1 or 2\n7. Life expectancy of at least 3 months\n8. Adequate bone marrow, renal, and hepatic function\n\nInclusion Criteria (Part B)\n\n1. Written informed consent by the patient prior to screening\n2. Patients aged ≥ 18 years on the day of consenting to the study\n3. Pathologic diagnosis of PCNSL within the past 3 months\n4. No prior anti-tumor treatments for PCNSL\n5. Patients who, in the opinion of the Investigator, are suitable to receive treatment with a high dose methotrexate containing regimen\n6. Measurable brain lesion with a minimum diameter > 1.0 cm in gadolinium enhanced MRI performed within 14 days before starting study treatment\n7. ECOG PS of 0, 1 or 2\n8. Life expectancy of at least 6 months\n9. Adequate bone marrow, renal, and hepatic function\n\nExclusion Criteria (Part A)\n\n1. Intraocular PCNSL with no brain lesion\n2. Patient who is intolerant of contrast enhanced MRI due to allergic reactions to contrast agents\n3. Patient with non-B cell PCNSL\n4. Patient with systemic presence of lymphoma\n5. Prior chemotherapy within 21 days, nitrosourea within 42 days, an antibody drug with anticancer activity (e.g., rituximab) within 28 days, prior radiotherapy within 14 days, prior major invasive surgery within 28 days, or allogeneic stem cell transplant within 6 months before starting tirabrutinib treatment\n6. Prior BTK inhibitor treatment\n7. Prior investigational drugs (including treatment in clinical research, unapproved combination products, and new dosage forms) within 28 days or 5 half-lives, whichever is shorter, before starting tirabrutinib treatment\n8. Concomitant systemic corticosteroid on an ongoing basis within 14 days before starting tirabrutinib treatment, with the exception of the following:\n\n   * Equivalent of up to 10 mg/day of prednisone for a disease other than PCNSL\n   * Equivalent of up to 50 mg/day of prednisone (equal to 8 mg/day of dexamethasone) for patients with lesions of the brain or spinal cord or both\n9. Patient who has received a CYP3A4 inducer or P-gp inducer within 14 days before starting tirabrutinib treatment\n10. Concomitant warfarin, any other warfarin derivative anticoagulant, vitamin K antagonists, novel oral anticoagulants, or antiplatelet therapy on an ongoing basis within 7 days before starting tirabrutinib treatment\n11. Active malignancy, other than PCNSL requiring systemic therapy\n12. Poorly controlled comorbidity, severe heart, severe lung disease, clinically significant liver diseases that could affect protocol compliance or safety or efficacy assessments\n13. Patient with bleeding diathesis\n14. Patients with a history of moderate or severe hepatic impairment\n15. QTcF > 480 milliseconds or requirement for ongoing treatment with concomitant medications that prolong the QT interval\n16. Active infection, including a HIV, cytomegalovirus infection or SARS-CoV-2, or has had, within 28 days before starting tirabrutinib treatment, an infection (other than nail trichophytosis) that requires hospitalization or an intravenous antibiotic\n17. Prior history of hypersensitivity or anaphylaxis to tirabrutinib\n18. Prior history of Stevens Johnson Syndrome or Toxic Epidermal Necrolysis\n19. Medical history of organ allografts\n20. Tests positive for HIV-1 antibody and HIV-2 antibody, human T-lymphotropic virus 1 antibody, hepatitis B (HB) antigen, or hepatitis C virus (HCV) antibody. Tests positive for HBs antibody or hepatitis B virus core protein antibody and has a result of at least detectable in a hepatitis B virus deoxyribonucleic acid assay despite testing negative for HBs antigen.\n21. Patient is unable to swallow tablets; has malabsorption, malabsorption syndrome, or a comorbidity that affects gastric function; has undergone complete resection of the stomach or small intestine; has ulcerative colitis or symptomatic inflammatory bowel disease; or has partial or complete intestinal obstruction.\n22. Women who are pregnant or lactating\n23. Patient is found incapable of giving consent due to dementia or another such condition\n24. Patient is found to be otherwise ineligible for the study by the Investigator or sub-Investigator.\n\nExclusion Criteria (Part B)\n\n1. Intraocular PCNSL with no brain lesion\n2. Patients for whom the selected backbone regimen medications (i.e, methotrexate/temozolomide/rituximab for MTR and rituximab/methotrexate/procarbazine/vincristine for R-MPV) are contraindicated\n3. Patients with a history of intolerable toxicity, hypersensitivity, anaphylaxis to the selected backbone regimen medications\n4. Patient who is intolerant of contrast enhanced MRI due to allergic reactions to contrast agents\n5. Patient with non-B cell PCNSL\n6. Patient with systemic presence of lymphoma\n7. Prior chemotherapy within 21 days, nitrosourea within 42 days, an antibody drug with anticancer activity (e.g., rituximab) within 28 days, prior radiotherapy within 14 days, prior major invasive surgery within 28 days, or allogeneic stem cell transplant within 6 months before starting tirabrutinib treatment\n8. Prior BTK inhibitor treatment\n9. Prior investigational drugs (including treatment in clinical research, unapproved combination products, and new dosage forms) within 28 days or 5 half-lives, whichever is shorter, before starting tirabrutinib treatment\n10. Concomitant systemic corticosteroid on an ongoing basis within 14 days before starting tirabrutinib treatment, with the exception of the following:\n\n    * Equivalent of up to 10 mg/day of prednisone for a disease other than PCNSL\n    * Equivalent of up to 50 mg/day of prednisone (equal to 8 mg/day of dexamethasone) for patients with lesions of the brain or spinal cord or both\n11. Patient who has received a CYP3A4 inducer or P-gp inducer within 14 days before starting tirabrutinib treatment\n12. Concomitant warfarin, any other warfarin derivative anticoagulant, vitamin K antagonists, novel oral anticoagulants, or antiplatelet therapy on an ongoing basis within 7 days before starting tirabrutinib treatment\n13. Active malignancy, other than PCNSL requiring systemic therapy\n14. Poorly controlled comorbidity, severe heart, severe lung disease, clinically significant liver diseases that could affect protocol compliance or safety or efficacy assessments\n15. Patient with bleeding diathesis\n16. Patients with a history of moderate or severe hepatic impairment\n17. QTcF > 480 milliseconds or requirement for ongoing treatment with concomitant medications that prolong the QT interval\n18. Active infection, including a HIV, cytomegalovirus infection or SARS-CoV-2, or has had, within 28 days before starting tirabrutinib treatment, an infection (other than nail trichophytosis) that requires hospitalization or an intravenous antibiotic\n19. Prior history of hypersensitivity or anaphylaxis to tirabrutinib\n20. Prior history of Stevens Johnson Syndrome or Toxic Epidermal Necrolysis\n21. Medical history of organ allografts\n22. Tests positive for HIV-1 antibody and HIV-2 antibody, human T-lymphotropic virus 1 antibody, HBs antigen, or HCV antibody. Tests positive for HBs antibody or hepatitis B virus core protein antibody and has a result of at least detectable in a hepatitis B virus deoxyribonucleic acid assay despite testing negative for HBs antigen.\n23. Patient is unable to swallow tablets; has malabsorption, malabsorption syndrome, or a comorbidity that affects gastric function; has undergone complete resection of the stomach or small intestine; has ulcerative colitis or symptomatic inflammatory bowel disease; or has partial or complete intestinal obstruction.\n24. Women who are pregnant or lactating\n25. Patient is found incapable of giving consent due to dementia or another such condition\n26. Patient is found to be otherwise ineligible for the study by the Investigator or sub-Investigator.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
        "exclusion_criteria": "",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "line": "11. Active malignancy, other than PCNSL requiring systemic therapy",
            "criterions": [
                {
                    "exact_snippets": "Active malignancy, other than PCNSL requiring systemic therapy",
                    "criterion": "active malignancy (other than PCNSL)",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "requires systemic therapy",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have minimum age of 18 Years",
            "criterions": [
                {
                    "exact_snippets": "minimum age of 18 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "10. Concomitant systemic corticosteroid on an ongoing basis within 14 days before starting tirabrutinib treatment, with the exception of the following:",
            "criterions": [
                {
                    "exact_snippets": "Concomitant systemic corticosteroid on an ongoing basis within 14 days before starting tirabrutinib treatment",
                    "criterion": "systemic corticosteroid use",
                    "requirements": [
                        {
                            "requirement_type": "concomitant use",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "ongoing basis",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "time window before starting tirabrutinib",
                            "expected_value": {
                                "operator": "<=",
                                "value": 14,
                                "unit": "days"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "8. Life expectancy of at least 6 months",
            "criterions": [
                {
                    "exact_snippets": "Life expectancy of at least 6 months",
                    "criterion": "life expectancy",
                    "requirements": [
                        {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "13. Active malignancy, other than PCNSL requiring systemic therapy",
            "criterions": [
                {
                    "exact_snippets": "Active malignancy, other than PCNSL requiring systemic therapy",
                    "criterion": "active malignancy (other than PCNSL)",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "requires systemic therapy",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "24. Women who are pregnant or lactating",
            "criterions": [
                {
                    "exact_snippets": "Women who are pregnant",
                    "criterion": "pregnancy status",
                    "requirements": [
                        {
                            "requirement_type": "pregnant",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Women who are ... lactating",
                    "criterion": "lactation status",
                    "requirements": [
                        {
                            "requirement_type": "lactating",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "7. Prior investigational drugs (including treatment in clinical research, unapproved combination products, and new dosage forms) within 28 days or 5 half-lives, whichever is shorter, before starting tirabrutinib treatment",
            "criterions": [
                {
                    "exact_snippets": "Prior investigational drugs (including treatment in clinical research, unapproved combination products, and new dosage forms) within 28 days or 5 half-lives, whichever is shorter, before starting tirabrutinib treatment",
                    "criterion": "prior investigational drug use",
                    "requirements": [
                        {
                            "requirement_type": "absence_within_timeframe",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 28,
                                        "unit": "days"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 5,
                                        "unit": "half-lives"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "3. Pathologic diagnosis of PCNSL within the past 3 months",
            "criterions": [
                {
                    "exact_snippets": "Pathologic diagnosis of PCNSL",
                    "criterion": "pathologic diagnosis of PCNSL",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "within the past 3 months",
                    "criterion": "time since pathologic diagnosis of PCNSL",
                    "requirements": [
                        {
                            "requirement_type": "time since diagnosis",
                            "expected_value": {
                                "operator": "<=",
                                "value": 3,
                                "unit": "months"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "21. Medical history of organ allografts",
            "criterions": [
                {
                    "exact_snippets": "Medical history of organ allografts",
                    "criterion": "organ allograft",
                    "requirements": [
                        {
                            "requirement_type": "medical history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "21. Patient is unable to swallow tablets; has malabsorption, malabsorption syndrome, or a comorbidity that affects gastric function; has undergone complete resection of the stomach or small intestine; has ulcerative colitis or symptomatic inflammatory bowel disease; or has partial or complete intestinal obstruction.",
            "criterions": [
                {
                    "exact_snippets": "unable to swallow tablets",
                    "criterion": "ability to swallow tablets",
                    "requirements": [
                        {
                            "requirement_type": "ability",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "has malabsorption, malabsorption syndrome",
                    "criterion": "malabsorption",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "comorbidity that affects gastric function",
                    "criterion": "comorbidity affecting gastric function",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "undergone complete resection of the stomach or small intestine",
                    "criterion": "complete resection of the stomach or small intestine",
                    "requirements": [
                        {
                            "requirement_type": "history of surgery",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "has ulcerative colitis",
                    "criterion": "ulcerative colitis",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "symptomatic inflammatory bowel disease",
                    "criterion": "symptomatic inflammatory bowel disease",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "partial or complete intestinal obstruction",
                    "criterion": "intestinal obstruction",
                    "requirements": [
                        {
                            "requirement_type": "degree",
                            "expected_value": [
                                "partial",
                                "complete"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "2. Patients for whom the selected backbone regimen medications (i.e, methotrexate/temozolomide/rituximab for MTR and rituximab/methotrexate/procarbazine/vincristine for R-MPV) are contraindicated",
            "criterions": [
                {
                    "exact_snippets": "Patients for whom the selected backbone regimen medications (i.e, methotrexate/temozolomide/rituximab for MTR and rituximab/methotrexate/procarbazine/vincristine for R-MPV) are contraindicated",
                    "criterion": "contraindication to backbone regimen medications",
                    "requirements": [
                        {
                            "requirement_type": "contraindication",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Equivalent of up to 50 mg/day of prednisone (equal to 8 mg/day of dexamethasone) for patients with lesions of the brain or spinal cord or both",
            "criterions": [
                {
                    "exact_snippets": "Equivalent of up to 50 mg/day of prednisone (equal to 8 mg/day of dexamethasone)",
                    "criterion": "corticosteroid dosage",
                    "requirements": [
                        {
                            "requirement_type": "maximum dosage",
                            "expected_value": {
                                "operator": "<=",
                                "value": 50,
                                "unit": "mg/day prednisone equivalent"
                            }
                        },
                        {
                            "requirement_type": "maximum dosage",
                            "expected_value": {
                                "operator": "<=",
                                "value": 8,
                                "unit": "mg/day dexamethasone equivalent"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "for patients with lesions of the brain or spinal cord or both",
                    "criterion": "lesions location",
                    "requirements": [
                        {
                            "requirement_type": "location",
                            "expected_value": [
                                "brain",
                                "spinal cord"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "20. Prior history of Stevens Johnson Syndrome or Toxic Epidermal Necrolysis",
            "criterions": [
                {
                    "exact_snippets": "Prior history of Stevens Johnson Syndrome",
                    "criterion": "Stevens Johnson Syndrome",
                    "requirements": [
                        {
                            "requirement_type": "prior history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Prior history of ... Toxic Epidermal Necrolysis",
                    "criterion": "Toxic Epidermal Necrolysis",
                    "requirements": [
                        {
                            "requirement_type": "prior history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "15. Patient with bleeding diathesis",
            "criterions": [
                {
                    "exact_snippets": "Patient with bleeding diathesis",
                    "criterion": "bleeding diathesis",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "24. Patient is found to be otherwise ineligible for the study by the Investigator or sub-Investigator.",
            "criterions": [
                {
                    "exact_snippets": "Patient is found to be otherwise ineligible for the study by the Investigator or sub-Investigator.",
                    "criterion": "investigator-determined eligibility",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "13. Patient with bleeding diathesis",
            "criterions": [
                {
                    "exact_snippets": "Patient with bleeding diathesis",
                    "criterion": "bleeding diathesis",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "8. Concomitant systemic corticosteroid on an ongoing basis within 14 days before starting tirabrutinib treatment, with the exception of the following:",
            "criterions": [
                {
                    "exact_snippets": "Concomitant systemic corticosteroid on an ongoing basis within 14 days before starting tirabrutinib treatment",
                    "criterion": "systemic corticosteroid use",
                    "requirements": [
                        {
                            "requirement_type": "concomitant use",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "ongoing basis",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "time window",
                            "expected_value": {
                                "operator": "<=",
                                "value": 14,
                                "unit": "days before starting tirabrutinib treatment"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "Healthy volunteers allowed",
            "criterions": [
                {
                    "exact_snippets": "Healthy volunteers allowed",
                    "criterion": "healthy volunteer status",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "5. Measurable brain lesion with a minimum diameter > 1.0 cm in gadolinium enhanced magnetic resonance imaging (MRI) performed within 14 days before starting tirabrutinib treatment",
            "criterions": [
                {
                    "exact_snippets": "Measurable brain lesion with a minimum diameter > 1.0 cm",
                    "criterion": "brain lesion",
                    "requirements": [
                        {
                            "requirement_type": "measurability",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "size",
                            "expected_value": {
                                "operator": ">",
                                "value": 1.0,
                                "unit": "cm"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "in gadolinium enhanced magnetic resonance imaging (MRI)",
                    "criterion": "imaging modality",
                    "requirements": [
                        {
                            "requirement_type": "modality",
                            "expected_value": "gadolinium enhanced MRI"
                        }
                    ]
                },
                {
                    "exact_snippets": "performed within 14 days before starting tirabrutinib treatment",
                    "criterion": "MRI timing",
                    "requirements": [
                        {
                            "requirement_type": "time before treatment",
                            "expected_value": {
                                "operator": "<=",
                                "value": 14,
                                "unit": "days"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "9. Prior investigational drugs (including treatment in clinical research, unapproved combination products, and new dosage forms) within 28 days or 5 half-lives, whichever is shorter, before starting tirabrutinib treatment",
            "criterions": [
                {
                    "exact_snippets": "Prior investigational drugs (including treatment in clinical research, unapproved combination products, and new dosage forms) within 28 days or 5 half-lives, whichever is shorter, before starting tirabrutinib treatment",
                    "criterion": "prior investigational drug use",
                    "requirements": [
                        {
                            "requirement_type": "absence_within_timeframe",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 28,
                                        "unit": "days"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 5,
                                        "unit": "half-lives"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "18. Active infection, including a HIV, cytomegalovirus infection or SARS-CoV-2, or has had, within 28 days before starting tirabrutinib treatment, an infection (other than nail trichophytosis) that requires hospitalization or an intravenous antibiotic",
            "criterions": [
                {
                    "exact_snippets": "Active infection",
                    "criterion": "active infection",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "including a HIV, cytomegalovirus infection or SARS-CoV-2",
                    "criterion": "specific active infections",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": [
                                "HIV",
                                "cytomegalovirus infection",
                                "SARS-CoV-2"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "has had, within 28 days before starting tirabrutinib treatment, an infection (other than nail trichophytosis) that requires hospitalization or an intravenous antibiotic",
                    "criterion": "recent serious infection",
                    "requirements": [
                        {
                            "requirement_type": "time since infection",
                            "expected_value": {
                                "operator": "<=",
                                "value": 28,
                                "unit": "days"
                            }
                        },
                        {
                            "requirement_type": "treatment required",
                            "expected_value": [
                                "hospitalization",
                                "intravenous antibiotic"
                            ]
                        },
                        {
                            "requirement_type": "infection type exclusion",
                            "expected_value": "not nail trichophytosis"
                        }
                    ]
                }
            ]
        },
        {
            "line": "17. Prior history of hypersensitivity or anaphylaxis to tirabrutinib",
            "criterions": [
                {
                    "exact_snippets": "Prior history of hypersensitivity ... to tirabrutinib",
                    "criterion": "hypersensitivity to tirabrutinib",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Prior history of ... anaphylaxis to tirabrutinib",
                    "criterion": "anaphylaxis to tirabrutinib",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "14. Poorly controlled comorbidity, severe heart, severe lung disease, clinically significant liver diseases that could affect protocol compliance or safety or efficacy assessments",
            "criterions": [
                {
                    "exact_snippets": "Poorly controlled comorbidity",
                    "criterion": "comorbidity",
                    "requirements": [
                        {
                            "requirement_type": "control",
                            "expected_value": "poorly controlled"
                        }
                    ]
                },
                {
                    "exact_snippets": "severe heart",
                    "criterion": "heart disease",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": "severe"
                        }
                    ]
                },
                {
                    "exact_snippets": "severe lung disease",
                    "criterion": "lung disease",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": "severe"
                        }
                    ]
                },
                {
                    "exact_snippets": "clinically significant liver diseases",
                    "criterion": "liver disease",
                    "requirements": [
                        {
                            "requirement_type": "clinical significance",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "7. Prior chemotherapy within 21 days, nitrosourea within 42 days, an antibody drug with anticancer activity (e.g., rituximab) within 28 days, prior radiotherapy within 14 days, prior major invasive surgery within 28 days, or allogeneic stem cell transplant within 6 months before starting tirabrutinib treatment",
            "criterions": [
                {
                    "exact_snippets": "Prior chemotherapy within 21 days",
                    "criterion": "prior chemotherapy",
                    "requirements": [
                        {
                            "requirement_type": "time since last treatment",
                            "expected_value": {
                                "operator": ">",
                                "value": 21,
                                "unit": "days"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "nitrosourea within 42 days",
                    "criterion": "prior nitrosourea treatment",
                    "requirements": [
                        {
                            "requirement_type": "time since last treatment",
                            "expected_value": {
                                "operator": ">",
                                "value": 42,
                                "unit": "days"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "an antibody drug with anticancer activity (e.g., rituximab) within 28 days",
                    "criterion": "prior antibody drug with anticancer activity",
                    "requirements": [
                        {
                            "requirement_type": "time since last treatment",
                            "expected_value": {
                                "operator": ">",
                                "value": 28,
                                "unit": "days"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "prior radiotherapy within 14 days",
                    "criterion": "prior radiotherapy",
                    "requirements": [
                        {
                            "requirement_type": "time since last treatment",
                            "expected_value": {
                                "operator": ">",
                                "value": 14,
                                "unit": "days"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "prior major invasive surgery within 28 days",
                    "criterion": "prior major invasive surgery",
                    "requirements": [
                        {
                            "requirement_type": "time since last surgery",
                            "expected_value": {
                                "operator": ">",
                                "value": 28,
                                "unit": "days"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "allogeneic stem cell transplant within 6 months",
                    "criterion": "prior allogeneic stem cell transplant",
                    "requirements": [
                        {
                            "requirement_type": "time since last transplant",
                            "expected_value": {
                                "operator": ">",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "5. Prior chemotherapy within 21 days, nitrosourea within 42 days, an antibody drug with anticancer activity (e.g., rituximab) within 28 days, prior radiotherapy within 14 days, prior major invasive surgery within 28 days, or allogeneic stem cell transplant within 6 months before starting tirabrutinib treatment",
            "criterions": [
                {
                    "exact_snippets": "Prior chemotherapy within 21 days ... before starting tirabrutinib treatment",
                    "criterion": "prior chemotherapy",
                    "requirements": [
                        {
                            "requirement_type": "time since last treatment",
                            "expected_value": {
                                "operator": ">",
                                "value": 21,
                                "unit": "days"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "nitrosourea within 42 days ... before starting tirabrutinib treatment",
                    "criterion": "prior nitrosourea treatment",
                    "requirements": [
                        {
                            "requirement_type": "time since last treatment",
                            "expected_value": {
                                "operator": ">",
                                "value": 42,
                                "unit": "days"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "an antibody drug with anticancer activity (e.g., rituximab) within 28 days ... before starting tirabrutinib treatment",
                    "criterion": "prior antibody drug with anticancer activity",
                    "requirements": [
                        {
                            "requirement_type": "time since last treatment",
                            "expected_value": {
                                "operator": ">",
                                "value": 28,
                                "unit": "days"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "prior radiotherapy within 14 days ... before starting tirabrutinib treatment",
                    "criterion": "prior radiotherapy",
                    "requirements": [
                        {
                            "requirement_type": "time since last treatment",
                            "expected_value": {
                                "operator": ">",
                                "value": 14,
                                "unit": "days"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "prior major invasive surgery within 28 days ... before starting tirabrutinib treatment",
                    "criterion": "prior major invasive surgery",
                    "requirements": [
                        {
                            "requirement_type": "time since last treatment",
                            "expected_value": {
                                "operator": ">",
                                "value": 28,
                                "unit": "days"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "allogeneic stem cell transplant within 6 months before starting tirabrutinib treatment",
                    "criterion": "prior allogeneic stem cell transplant",
                    "requirements": [
                        {
                            "requirement_type": "time since last treatment",
                            "expected_value": {
                                "operator": ">",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "4. Relapse or refractory PCNSL with at least one prior high dose methotrexate (HD-MTX) based therapy for PCNSL",
            "criterions": [
                {
                    "exact_snippets": "Relapse or refractory PCNSL",
                    "criterion": "PCNSL disease status",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": [
                                "relapse",
                                "refractory"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "at least one prior high dose methotrexate (HD-MTX) based therapy for PCNSL",
                    "criterion": "prior HD-MTX based therapy for PCNSL",
                    "requirements": [
                        {
                            "requirement_type": "number of prior therapies",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "therapy"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "17. QTcF > 480 milliseconds or requirement for ongoing treatment with concomitant medications that prolong the QT interval",
            "criterions": [
                {
                    "exact_snippets": "QTcF > 480 milliseconds",
                    "criterion": "QTcF interval",
                    "requirements": [
                        {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": ">",
                                "value": 480,
                                "unit": "milliseconds"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "requirement for ongoing treatment with concomitant medications that prolong the QT interval",
                    "criterion": "concomitant medications that prolong the QT interval",
                    "requirements": [
                        {
                            "requirement_type": "ongoing treatment requirement",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "2. Patients aged ≥ 18 years on the day of consenting to the study",
            "criterions": [
                {
                    "exact_snippets": "Patients aged ≥ 18 years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum age",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "6. Measurable brain lesion with a minimum diameter > 1.0 cm in gadolinium enhanced MRI performed within 14 days before starting study treatment",
            "criterions": [
                {
                    "exact_snippets": "Measurable brain lesion with a minimum diameter > 1.0 cm",
                    "criterion": "brain lesion",
                    "requirements": [
                        {
                            "requirement_type": "measurability",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "size",
                            "expected_value": {
                                "operator": ">",
                                "value": 1.0,
                                "unit": "cm"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "gadolinium enhanced MRI performed within 14 days before starting study treatment",
                    "criterion": "gadolinium enhanced MRI",
                    "requirements": [
                        {
                            "requirement_type": "performance time",
                            "expected_value": "within 14 days before starting study treatment"
                        }
                    ]
                }
            ]
        },
        {
            "line": "1. Written informed consent by the patient prior to screening",
            "criterions": [
                {
                    "exact_snippets": "Written informed consent by the patient prior to screening",
                    "criterion": "informed consent",
                    "requirements": [
                        {
                            "requirement_type": "type",
                            "expected_value": "written"
                        },
                        {
                            "requirement_type": "timing",
                            "expected_value": "prior to screening"
                        },
                        {
                            "requirement_type": "provider",
                            "expected_value": "patient"
                        }
                    ]
                }
            ]
        },
        {
            "line": "16. Patients with a history of moderate or severe hepatic impairment",
            "criterions": [
                {
                    "exact_snippets": "history of moderate or severe hepatic impairment",
                    "criterion": "hepatic impairment",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "severity",
                            "expected_value": [
                                "moderate",
                                "severe"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "26. Patient is found to be otherwise ineligible for the study by the Investigator or sub-Investigator.",
            "criterions": [
                {
                    "exact_snippets": "Patient is found to be otherwise ineligible for the study by the Investigator or sub-Investigator.",
                    "criterion": "investigator-determined eligibility",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": false
                        },
                        {
                            "requirement_type": "determined_by",
                            "expected_value": [
                                "Investigator",
                                "sub-Investigator"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "2. Patients aged ≥ 18 years on the day of consenting to the study",
            "criterions": [
                {
                    "exact_snippets": "Patients aged ≥ 18 years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum age",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "Exclusion Criteria (Part B)",
            "criterions": [
                {
                    "exact_snippets": "Exclusion Criteria (Part B)",
                    "criterion": "exclusion criteria for Part B",
                    "requirements": [
                        {
                            "requirement_type": "applicability",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "12. Poorly controlled comorbidity, severe heart, severe lung disease, clinically significant liver diseases that could affect protocol compliance or safety or efficacy assessments",
            "criterions": [
                {
                    "exact_snippets": "Poorly controlled comorbidity",
                    "criterion": "comorbidity",
                    "requirements": [
                        {
                            "requirement_type": "control",
                            "expected_value": "poorly controlled"
                        }
                    ]
                },
                {
                    "exact_snippets": "severe heart",
                    "criterion": "heart disease",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": "severe"
                        }
                    ]
                },
                {
                    "exact_snippets": "severe lung disease",
                    "criterion": "lung disease",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": "severe"
                        }
                    ]
                },
                {
                    "exact_snippets": "clinically significant liver diseases",
                    "criterion": "liver disease",
                    "requirements": [
                        {
                            "requirement_type": "clinical significance",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "5. Patients who, in the opinion of the Investigator, are suitable to receive treatment with a high dose methotrexate containing regimen",
            "criterions": [
                {
                    "exact_snippets": "Patients who, in the opinion of the Investigator, are suitable to receive treatment with a high dose methotrexate containing regimen",
                    "criterion": "suitability for high dose methotrexate containing regimen",
                    "requirements": [
                        {
                            "requirement_type": "suitability",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "investigator opinion",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "7. Life expectancy of at least 3 months",
            "criterions": [
                {
                    "exact_snippets": "Life expectancy of at least 3 months",
                    "criterion": "life expectancy",
                    "requirements": [
                        {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 3,
                                "unit": "months"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "3. Pathologic diagnosis of PCNSL",
            "criterions": [
                {
                    "exact_snippets": "Pathologic diagnosis of PCNSL",
                    "criterion": "PCNSL (primary central nervous system lymphoma)",
                    "requirements": [
                        {
                            "requirement_type": "pathologic diagnosis",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "23. Patient is unable to swallow tablets; has malabsorption, malabsorption syndrome, or a comorbidity that affects gastric function; has undergone complete resection of the stomach or small intestine; has ulcerative colitis or symptomatic inflammatory bowel disease; or has partial or complete intestinal obstruction.",
            "criterions": [
                {
                    "exact_snippets": "unable to swallow tablets",
                    "criterion": "ability to swallow tablets",
                    "requirements": [
                        {
                            "requirement_type": "ability",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "has malabsorption, malabsorption syndrome",
                    "criterion": "malabsorption",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "comorbidity that affects gastric function",
                    "criterion": "comorbidity affecting gastric function",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "undergone complete resection of the stomach or small intestine",
                    "criterion": "complete resection of the stomach or small intestine",
                    "requirements": [
                        {
                            "requirement_type": "history of surgery",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "has ulcerative colitis",
                    "criterion": "ulcerative colitis",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "symptomatic inflammatory bowel disease",
                    "criterion": "symptomatic inflammatory bowel disease",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "partial or complete intestinal obstruction",
                    "criterion": "intestinal obstruction",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "22. Tests positive for HIV-1 antibody and HIV-2 antibody, human T-lymphotropic virus 1 antibody, HBs antigen, or HCV antibody. Tests positive for HBs antibody or hepatitis B virus core protein antibody and has a result of at least detectable in a hepatitis B virus deoxyribonucleic acid assay despite testing negative for HBs antigen.",
            "criterions": [
                {
                    "exact_snippets": "Tests positive for HIV-1 antibody",
                    "criterion": "HIV-1 antibody",
                    "requirements": [
                        {
                            "requirement_type": "test result",
                            "expected_value": "positive"
                        }
                    ]
                },
                {
                    "exact_snippets": "Tests positive for ... HIV-2 antibody",
                    "criterion": "HIV-2 antibody",
                    "requirements": [
                        {
                            "requirement_type": "test result",
                            "expected_value": "positive"
                        }
                    ]
                },
                {
                    "exact_snippets": "Tests positive for ... human T-lymphotropic virus 1 antibody",
                    "criterion": "human T-lymphotropic virus 1 antibody",
                    "requirements": [
                        {
                            "requirement_type": "test result",
                            "expected_value": "positive"
                        }
                    ]
                },
                {
                    "exact_snippets": "Tests positive for ... HBs antigen",
                    "criterion": "HBs antigen",
                    "requirements": [
                        {
                            "requirement_type": "test result",
                            "expected_value": "positive"
                        }
                    ]
                },
                {
                    "exact_snippets": "Tests positive for ... HCV antibody",
                    "criterion": "HCV antibody",
                    "requirements": [
                        {
                            "requirement_type": "test result",
                            "expected_value": "positive"
                        }
                    ]
                },
                {
                    "exact_snippets": "Tests positive for HBs antibody ... and has a result of at least detectable in a hepatitis B virus deoxyribonucleic acid assay despite testing negative for HBs antigen",
                    "criterion": "HBs antibody",
                    "requirements": [
                        {
                            "requirement_type": "test result",
                            "expected_value": "positive"
                        }
                    ]
                },
                {
                    "exact_snippets": "Tests positive for ... hepatitis B virus core protein antibody ... and has a result of at least detectable in a hepatitis B virus deoxyribonucleic acid assay despite testing negative for HBs antigen",
                    "criterion": "hepatitis B virus core protein antibody",
                    "requirements": [
                        {
                            "requirement_type": "test result",
                            "expected_value": "positive"
                        }
                    ]
                },
                {
                    "exact_snippets": "has a result of at least detectable in a hepatitis B virus deoxyribonucleic acid assay despite testing negative for HBs antigen",
                    "criterion": "hepatitis B virus deoxyribonucleic acid (HBV DNA)",
                    "requirements": [
                        {
                            "requirement_type": "test result",
                            "expected_value": {
                                "operator": ">=",
                                "value": 0,
                                "unit": "detectable"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "4. Patient with systemic presence of lymphoma",
            "criterions": [
                {
                    "exact_snippets": "systemic presence of lymphoma",
                    "criterion": "lymphoma",
                    "requirements": [
                        {
                            "requirement_type": "systemic presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "6. Prior BTK inhibitor treatment",
            "criterions": [
                {
                    "exact_snippets": "Prior BTK inhibitor treatment",
                    "criterion": "BTK inhibitor treatment",
                    "requirements": [
                        {
                            "requirement_type": "prior treatment",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "25. Patient is found incapable of giving consent due to dementia or another such condition",
            "criterions": [
                {
                    "exact_snippets": "incapable of giving consent due to dementia or another such condition",
                    "criterion": "capacity to give consent",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "dementia or another such condition",
                    "criterion": "dementia or similar condition",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "4. No prior anti-tumor treatments for PCNSL",
            "criterions": [
                {
                    "exact_snippets": "No prior anti-tumor treatments for PCNSL",
                    "criterion": "prior anti-tumor treatments for PCNSL",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "22. Women who are pregnant or lactating",
            "criterions": [
                {
                    "exact_snippets": "Women who are pregnant",
                    "criterion": "pregnancy status",
                    "requirements": [
                        {
                            "requirement_type": "pregnant",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Women who are ... lactating",
                    "criterion": "lactation status",
                    "requirements": [
                        {
                            "requirement_type": "lactating",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "19. Medical history of organ allografts",
            "criterions": [
                {
                    "exact_snippets": "Medical history of organ allografts",
                    "criterion": "organ allograft",
                    "requirements": [
                        {
                            "requirement_type": "medical history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "1. Intraocular PCNSL with no brain lesion",
            "criterions": [
                {
                    "exact_snippets": "Intraocular PCNSL",
                    "criterion": "intraocular primary central nervous system lymphoma (PCNSL)",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "no brain lesion",
                    "criterion": "brain lesion",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "1. Written informed consent by the patient prior to screening",
            "criterions": [
                {
                    "exact_snippets": "Written informed consent by the patient prior to screening",
                    "criterion": "informed consent",
                    "requirements": [
                        {
                            "requirement_type": "documentation",
                            "expected_value": "written"
                        },
                        {
                            "requirement_type": "timing",
                            "expected_value": "prior to screening"
                        },
                        {
                            "requirement_type": "provider",
                            "expected_value": "patient"
                        }
                    ]
                }
            ]
        },
        {
            "line": "4. Patient who is intolerant of contrast enhanced MRI due to allergic reactions to contrast agents",
            "criterions": [
                {
                    "exact_snippets": "intolerant of contrast enhanced MRI",
                    "criterion": "contrast enhanced MRI intolerance",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "due to allergic reactions to contrast agents",
                    "criterion": "allergic reactions to contrast agents",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "Inclusion Criteria (Part A)",
            "criterions": [
                {
                    "exact_snippets": "Inclusion Criteria (Part A)",
                    "criterion": "inclusion criteria for Part A",
                    "requirements": [
                        {
                            "requirement_type": "applicability",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "5. Patient with non-B cell PCNSL",
            "criterions": [
                {
                    "exact_snippets": "Patient with non-B cell PCNSL",
                    "criterion": "PCNSL subtype",
                    "requirements": [
                        {
                            "requirement_type": "subtype",
                            "expected_value": "non-B cell"
                        }
                    ]
                }
            ]
        },
        {
            "line": "18. Prior history of Stevens Johnson Syndrome or Toxic Epidermal Necrolysis",
            "criterions": [
                {
                    "exact_snippets": "Prior history of Stevens Johnson Syndrome",
                    "criterion": "Stevens Johnson Syndrome",
                    "requirements": [
                        {
                            "requirement_type": "prior history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Prior history of ... Toxic Epidermal Necrolysis",
                    "criterion": "Toxic Epidermal Necrolysis",
                    "requirements": [
                        {
                            "requirement_type": "prior history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "6. Eastern Cooperative Oncology Group performance score (ECOG PS) of 0, 1 or 2",
            "criterions": [
                {
                    "exact_snippets": "Eastern Cooperative Oncology Group performance score (ECOG PS) of 0, 1 or 2",
                    "criterion": "Eastern Cooperative Oncology Group performance score (ECOG PS)",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": [
                                "0",
                                "1",
                                "2"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "8. Adequate bone marrow, renal, and hepatic function",
            "criterions": [
                {
                    "exact_snippets": "Adequate bone marrow ... function",
                    "criterion": "bone marrow function",
                    "requirements": [
                        {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Adequate ... renal ... function",
                    "criterion": "renal function",
                    "requirements": [
                        {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Adequate ... hepatic function",
                    "criterion": "hepatic function",
                    "requirements": [
                        {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "14. Patients with a history of moderate or severe hepatic impairment",
            "criterions": [
                {
                    "exact_snippets": "history of moderate or severe hepatic impairment",
                    "criterion": "hepatic impairment",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "severity",
                            "expected_value": [
                                "moderate",
                                "severe"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "10. Concomitant warfarin, any other warfarin derivative anticoagulant, vitamin K antagonists, novel oral anticoagulants, or antiplatelet therapy on an ongoing basis within 7 days before starting tirabrutinib treatment",
            "criterions": [
                {
                    "exact_snippets": "Concomitant warfarin ... on an ongoing basis within 7 days before starting tirabrutinib treatment",
                    "criterion": "warfarin use",
                    "requirements": [
                        {
                            "requirement_type": "concomitant use",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "time window",
                            "expected_value": {
                                "operator": "<=",
                                "value": 7,
                                "unit": "days before starting tirabrutinib"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "any other warfarin derivative anticoagulant ... on an ongoing basis within 7 days before starting tirabrutinib treatment",
                    "criterion": "warfarin derivative anticoagulant use",
                    "requirements": [
                        {
                            "requirement_type": "concomitant use",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "time window",
                            "expected_value": {
                                "operator": "<=",
                                "value": 7,
                                "unit": "days before starting tirabrutinib"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "vitamin K antagonists ... on an ongoing basis within 7 days before starting tirabrutinib treatment",
                    "criterion": "vitamin K antagonist use",
                    "requirements": [
                        {
                            "requirement_type": "concomitant use",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "time window",
                            "expected_value": {
                                "operator": "<=",
                                "value": 7,
                                "unit": "days before starting tirabrutinib"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "novel oral anticoagulants ... on an ongoing basis within 7 days before starting tirabrutinib treatment",
                    "criterion": "novel oral anticoagulant use",
                    "requirements": [
                        {
                            "requirement_type": "concomitant use",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "time window",
                            "expected_value": {
                                "operator": "<=",
                                "value": 7,
                                "unit": "days before starting tirabrutinib"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "antiplatelet therapy on an ongoing basis within 7 days before starting tirabrutinib treatment",
                    "criterion": "antiplatelet therapy use",
                    "requirements": [
                        {
                            "requirement_type": "concomitant use",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "time window",
                            "expected_value": {
                                "operator": "<=",
                                "value": 7,
                                "unit": "days before starting tirabrutinib"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "3. Patients with a history of intolerable toxicity, hypersensitivity, anaphylaxis to the selected backbone regimen medications",
            "criterions": [
                {
                    "exact_snippets": "history of intolerable toxicity ... to the selected backbone regimen medications",
                    "criterion": "intolerable toxicity to backbone regimen medications",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "history of ... hypersensitivity ... to the selected backbone regimen medications",
                    "criterion": "hypersensitivity to backbone regimen medications",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "history of ... anaphylaxis to the selected backbone regimen medications",
                    "criterion": "anaphylaxis to backbone regimen medications",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Equivalent of up to 50 mg/day of prednisone (equal to 8 mg/day of dexamethasone) for patients with lesions of the brain or spinal cord or both",
            "criterions": [
                {
                    "exact_snippets": "Equivalent of up to 50 mg/day of prednisone (equal to 8 mg/day of dexamethasone)",
                    "criterion": "corticosteroid dosage",
                    "requirements": [
                        {
                            "requirement_type": "maximum dosage",
                            "expected_value": {
                                "operator": "<=",
                                "value": 50,
                                "unit": "mg/day prednisone"
                            }
                        },
                        {
                            "requirement_type": "maximum dosage",
                            "expected_value": {
                                "operator": "<=",
                                "value": 8,
                                "unit": "mg/day dexamethasone"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "for patients with lesions of the brain or spinal cord or both",
                    "criterion": "lesions location",
                    "requirements": [
                        {
                            "requirement_type": "location",
                            "expected_value": [
                                "brain",
                                "spinal cord"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "20. Tests positive for HIV-1 antibody and HIV-2 antibody, human T-lymphotropic virus 1 antibody, hepatitis B (HB) antigen, or hepatitis C virus (HCV) antibody. Tests positive for HBs antibody or hepatitis B virus core protein antibody and has a result of at least detectable in a hepatitis B virus deoxyribonucleic acid assay despite testing negative for HBs antigen.",
            "criterions": [
                {
                    "exact_snippets": "Tests positive for HIV-1 antibody",
                    "criterion": "HIV-1 antibody",
                    "requirements": [
                        {
                            "requirement_type": "test result",
                            "expected_value": "positive"
                        }
                    ]
                },
                {
                    "exact_snippets": "Tests positive for ... HIV-2 antibody",
                    "criterion": "HIV-2 antibody",
                    "requirements": [
                        {
                            "requirement_type": "test result",
                            "expected_value": "positive"
                        }
                    ]
                },
                {
                    "exact_snippets": "Tests positive for ... human T-lymphotropic virus 1 antibody",
                    "criterion": "human T-lymphotropic virus 1 antibody",
                    "requirements": [
                        {
                            "requirement_type": "test result",
                            "expected_value": "positive"
                        }
                    ]
                },
                {
                    "exact_snippets": "Tests positive for ... hepatitis B (HB) antigen",
                    "criterion": "hepatitis B antigen",
                    "requirements": [
                        {
                            "requirement_type": "test result",
                            "expected_value": "positive"
                        }
                    ]
                },
                {
                    "exact_snippets": "Tests positive for ... hepatitis C virus (HCV) antibody",
                    "criterion": "hepatitis C virus antibody",
                    "requirements": [
                        {
                            "requirement_type": "test result",
                            "expected_value": "positive"
                        }
                    ]
                },
                {
                    "exact_snippets": "Tests positive for HBs antibody or hepatitis B virus core protein antibody and has a result of at least detectable in a hepatitis B virus deoxyribonucleic acid assay despite testing negative for HBs antigen",
                    "criterion": "HBs antibody",
                    "requirements": [
                        {
                            "requirement_type": "test result",
                            "expected_value": "positive"
                        }
                    ]
                },
                {
                    "exact_snippets": "Tests positive for HBs antibody or hepatitis B virus core protein antibody and has a result of at least detectable in a hepatitis B virus deoxyribonucleic acid assay despite testing negative for HBs antigen",
                    "criterion": "hepatitis B virus core protein antibody",
                    "requirements": [
                        {
                            "requirement_type": "test result",
                            "expected_value": "positive"
                        }
                    ]
                },
                {
                    "exact_snippets": "has a result of at least detectable in a hepatitis B virus deoxyribonucleic acid assay despite testing negative for HBs antigen",
                    "criterion": "hepatitis B virus deoxyribonucleic acid assay",
                    "requirements": [
                        {
                            "requirement_type": "test result",
                            "expected_value": {
                                "operator": ">=",
                                "value": 0,
                                "unit": "detectable"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "despite testing negative for HBs antigen",
                    "criterion": "HBs antigen",
                    "requirements": [
                        {
                            "requirement_type": "test result",
                            "expected_value": "negative"
                        }
                    ]
                }
            ]
        },
        {
            "line": "19. Prior history of hypersensitivity or anaphylaxis to tirabrutinib",
            "criterions": [
                {
                    "exact_snippets": "Prior history of hypersensitivity or anaphylaxis to tirabrutinib",
                    "criterion": "hypersensitivity to tirabrutinib",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Prior history of hypersensitivity or anaphylaxis to tirabrutinib",
                    "criterion": "anaphylaxis to tirabrutinib",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "Exclusion Criteria (Part A)",
            "criterions": [
                {
                    "exact_snippets": "Exclusion Criteria (Part A)",
                    "criterion": "exclusion criteria for Part A",
                    "requirements": [
                        {
                            "requirement_type": "applicability",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Equivalent of up to 10 mg/day of prednisone for a disease other than PCNSL",
            "criterions": [
                {
                    "exact_snippets": "Equivalent of up to 10 mg/day of prednisone",
                    "criterion": "prednisone dosage",
                    "requirements": [
                        {
                            "requirement_type": "maximum dosage",
                            "expected_value": {
                                "operator": "<=",
                                "value": 10,
                                "unit": "mg/day"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "for a disease other than PCNSL",
                    "criterion": "disease indication for prednisone",
                    "requirements": [
                        {
                            "requirement_type": "exclusion",
                            "expected_value": "PCNSL"
                        }
                    ]
                }
            ]
        },
        {
            "line": "9. Adequate bone marrow, renal, and hepatic function",
            "criterions": [
                {
                    "exact_snippets": "Adequate bone marrow ... function",
                    "criterion": "bone marrow function",
                    "requirements": [
                        {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Adequate ... renal ... function",
                    "criterion": "renal function",
                    "requirements": [
                        {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Adequate ... hepatic function",
                    "criterion": "hepatic function",
                    "requirements": [
                        {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "7. ECOG PS of 0, 1 or 2",
            "criterions": [
                {
                    "exact_snippets": "ECOG PS of 0, 1 or 2",
                    "criterion": "ECOG performance status",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": [
                                "0",
                                "1",
                                "2"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "23. Patient is found incapable of giving consent due to dementia or another such condition",
            "criterions": [
                {
                    "exact_snippets": "incapable of giving consent",
                    "criterion": "capacity to give consent",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "dementia or another such condition",
                    "criterion": "dementia or similar condition",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "8. Prior BTK inhibitor treatment",
            "criterions": [
                {
                    "exact_snippets": "Prior BTK inhibitor treatment",
                    "criterion": "BTK inhibitor treatment",
                    "requirements": [
                        {
                            "requirement_type": "prior treatment",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "3. Patient with non-B cell PCNSL",
            "criterions": [
                {
                    "exact_snippets": "Patient with non-B cell PCNSL",
                    "criterion": "PCNSL subtype",
                    "requirements": [
                        {
                            "requirement_type": "subtype",
                            "expected_value": "non-B cell"
                        }
                    ]
                }
            ]
        },
        {
            "line": "15. QTcF > 480 milliseconds or requirement for ongoing treatment with concomitant medications that prolong the QT interval",
            "criterions": [
                {
                    "exact_snippets": "QTcF > 480 milliseconds",
                    "criterion": "QTcF interval",
                    "requirements": [
                        {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": ">",
                                "value": 480,
                                "unit": "milliseconds"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "requirement for ongoing treatment with concomitant medications that prolong the QT interval",
                    "criterion": "ongoing treatment with concomitant medications that prolong the QT interval",
                    "requirements": [
                        {
                            "requirement_type": "treatment requirement",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "16. Active infection, including a HIV, cytomegalovirus infection or SARS-CoV-2, or has had, within 28 days before starting tirabrutinib treatment, an infection (other than nail trichophytosis) that requires hospitalization or an intravenous antibiotic",
            "criterions": [
                {
                    "exact_snippets": "Active infection",
                    "criterion": "active infection",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "including a HIV, cytomegalovirus infection or SARS-CoV-2",
                    "criterion": "specific infections (HIV, cytomegalovirus, SARS-CoV-2)",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "has had, within 28 days before starting tirabrutinib treatment, an infection (other than nail trichophytosis) that requires hospitalization or an intravenous antibiotic",
                    "criterion": "recent serious infection (excluding nail trichophytosis)",
                    "requirements": [
                        {
                            "requirement_type": "time since infection",
                            "expected_value": {
                                "operator": "<=",
                                "value": 28,
                                "unit": "days"
                            }
                        },
                        {
                            "requirement_type": "treatment required",
                            "expected_value": [
                                "hospitalization",
                                "intravenous antibiotic"
                            ]
                        },
                        {
                            "requirement_type": "infection type",
                            "expected_value": {
                                "operator": "!=",
                                "value": 1,
                                "unit": "nail trichophytosis"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "6. Patient with systemic presence of lymphoma",
            "criterions": [
                {
                    "exact_snippets": "systemic presence of lymphoma",
                    "criterion": "lymphoma",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "systemic",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "12. Concomitant warfarin, any other warfarin derivative anticoagulant, vitamin K antagonists, novel oral anticoagulants, or antiplatelet therapy on an ongoing basis within 7 days before starting tirabrutinib treatment",
            "criterions": [
                {
                    "exact_snippets": "Concomitant warfarin ... on an ongoing basis within 7 days before starting tirabrutinib treatment",
                    "criterion": "warfarin use",
                    "requirements": [
                        {
                            "requirement_type": "concomitant use",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "time window",
                            "expected_value": {
                                "operator": "<=",
                                "value": 7,
                                "unit": "days before starting tirabrutinib treatment"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "any other warfarin derivative anticoagulant ... on an ongoing basis within 7 days before starting tirabrutinib treatment",
                    "criterion": "warfarin derivative anticoagulant use",
                    "requirements": [
                        {
                            "requirement_type": "concomitant use",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "time window",
                            "expected_value": {
                                "operator": "<=",
                                "value": 7,
                                "unit": "days before starting tirabrutinib treatment"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "vitamin K antagonists ... on an ongoing basis within 7 days before starting tirabrutinib treatment",
                    "criterion": "vitamin K antagonist use",
                    "requirements": [
                        {
                            "requirement_type": "concomitant use",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "time window",
                            "expected_value": {
                                "operator": "<=",
                                "value": 7,
                                "unit": "days before starting tirabrutinib treatment"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "novel oral anticoagulants ... on an ongoing basis within 7 days before starting tirabrutinib treatment",
                    "criterion": "novel oral anticoagulant use",
                    "requirements": [
                        {
                            "requirement_type": "concomitant use",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "time window",
                            "expected_value": {
                                "operator": "<=",
                                "value": 7,
                                "unit": "days before starting tirabrutinib treatment"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "antiplatelet therapy on an ongoing basis within 7 days before starting tirabrutinib treatment",
                    "criterion": "antiplatelet therapy use",
                    "requirements": [
                        {
                            "requirement_type": "concomitant use",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "time window",
                            "expected_value": {
                                "operator": "<=",
                                "value": 7,
                                "unit": "days before starting tirabrutinib treatment"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "2. Patient who is intolerant of contrast enhanced MRI due to allergic reactions to contrast agents",
            "criterions": [
                {
                    "exact_snippets": "intolerant of contrast enhanced MRI",
                    "criterion": "contrast enhanced MRI intolerance",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "due to allergic reactions to contrast agents",
                    "criterion": "allergic reactions to contrast agents",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Equivalent of up to 10 mg/day of prednisone for a disease other than PCNSL",
            "criterions": [
                {
                    "exact_snippets": "Equivalent of up to 10 mg/day of prednisone",
                    "criterion": "prednisone dosage",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 10,
                                "unit": "mg/day"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "for a disease other than PCNSL",
                    "criterion": "disease indication for prednisone",
                    "requirements": [
                        {
                            "requirement_type": "exclusion",
                            "expected_value": "PCNSL"
                        }
                    ]
                }
            ]
        },
        {
            "line": "1. Intraocular PCNSL with no brain lesion",
            "criterions": [
                {
                    "exact_snippets": "Intraocular PCNSL",
                    "criterion": "intraocular primary central nervous system lymphoma (PCNSL)",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "no brain lesion",
                    "criterion": "brain lesion",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                }
            ]
        }
    ],
    "exclusion_lines": [],
    "miscellaneous_lines": [],
    "failed_inclusion": [
        {
            "line": "9. Patient who has received a CYP3A4 inducer or P-gp inducer within 14 days before starting tirabrutinib treatment",
            "criterions": [
                {
                    "exact_snippets": "received a CYP3A4 inducer within 14 days before starting tirabrutinib treatment",
                    "criterion": "CYP3A4 inducer administration",
                    "requirements": [
                        {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 14,
                                "unit": "days before starting tirabrutinib treatment"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "received a ... P-gp inducer within 14 days before starting tirabrutinib treatment",
                    "criterion": "P-gp inducer administration",
                    "requirements": [
                        {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 14,
                                "unit": "days before starting tirabrutinib treatment"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "Inclusion Criteria (Part B)",
            "criterions": []
        },
        {
            "line": "11. Patient who has received a CYP3A4 inducer or P-gp inducer within 14 days before starting tirabrutinib treatment",
            "criterions": [
                {
                    "exact_snippets": "received a CYP3A4 inducer within 14 days before starting tirabrutinib treatment",
                    "criterion": "CYP3A4 inducer administration",
                    "requirements": [
                        {
                            "requirement_type": "time since last administration",
                            "expected_value": {
                                "operator": "<=",
                                "value": 14,
                                "unit": "days"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "received a ... P-gp inducer within 14 days before starting tirabrutinib treatment",
                    "criterion": "P-gp inducer administration",
                    "requirements": [
                        {
                            "requirement_type": "time since last administration",
                            "expected_value": {
                                "operator": "<=",
                                "value": 14,
                                "unit": "days"
                            }
                        }
                    ]
                }
            ]
        }
    ],
    "failed_exclusion": [],
    "failed_miscellaneous": []
}